European and U.S. Regulators Agree on Mutual Recognition of Inspections
Regulators in the European Union (EU) and the U.S. have agreed to recognize inspections of manufacturing sites for human medicines conducted in their respective territories on both sides of the Atlantic.
Regulators in the European Union (EU) and the U.S. have agreed to recognize inspections of manufacturing sites for human medicines conducted in their respective territories on both sides of the Atlantic.
Under the deal, regulators will rely on each other’s inspections of production sites of medicinal products to ensure compliance with Good Manufacturing Practice (GMP). In the future, the need for an EU authority to inspect a site located in the U.S., or vice versa, will be limited to exceptional circumstances, according to a press release issued on March 2nd by the European Medicines Agency (EMA).
The agreement will enable both the EU authorities and the FDA to make better use of their inspection resources to help them to focus on other parts of the world where active pharmaceutical ingredients (APIs) and medicines for the EU or U.S. markets are manufactured, noted the EMA.
“This will ensure that patients can rely on the quality, safety and efficacy of all medicines, no matter where they have been produced. Around 40% of finished medicines marketed in the EU come from overseas and 80% of the manufacturers of APIs for medicines available in the EU are located outside the Union,” it stated.
In the EU, inspections of manufacturing sites are carried out by national competent authorities from EU member states, but EMA helps coordinate these activities.
The agreement is an annex to the EU-US Mutual Recognition Agreement (MRA), which was signed in 1998 but is not yet implemented. Many provisions of the agreement have already entered into force and others will enter into force on November 1st 2017, the statement continued. By that date, the EU will have completed its assessment of the FDA and the FDA is expected to have completed its assessment of at least eight EU member states, and will be gradually expanded to all member states. The text of this agreement is now published on the website of the European Commission’s Directorate General for Trade.
Philip Ward is the European Editor for Applied Clinical Trials
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
